2008
DOI: 10.1157/13128727
|View full text |Cite
|
Sign up to set email alerts
|

Nuevos tratamientos de la enfermedad arterial periférica oclusiva no revascularizable: angiogenia terapéutica

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2010
2010
2015
2015

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 41 publications
0
1
0
1
Order By: Relevance
“…Although therapies involving cytokine-transduced EPCs (e.g., SDF-1 and VEGF) can have profound and multifaceted effects on neovascularization [16], [17], the results in phase I/IIa of clinical trials show certain adverse effects. For instance, in a VEGF trial, 60% of the patients developed moderate or severe edema [18], [19]. The effects of therapy involving cytokine-transduced EPCs for wound healing have not yet been proven in a controlled clinical trial.…”
Section: Introductionmentioning
confidence: 99%
“…Although therapies involving cytokine-transduced EPCs (e.g., SDF-1 and VEGF) can have profound and multifaceted effects on neovascularization [16], [17], the results in phase I/IIa of clinical trials show certain adverse effects. For instance, in a VEGF trial, 60% of the patients developed moderate or severe edema [18], [19]. The effects of therapy involving cytokine-transduced EPCs for wound healing have not yet been proven in a controlled clinical trial.…”
Section: Introductionmentioning
confidence: 99%
“…En estos casos se aplican alternativas cuyo objetivo es paliar los síntomas y los efectos de esta enfermedad. Entre estas medidas se encuentran la simpatectomía lumbar, la administración de prostaglandinas por vía parenteral, la angiogénesis terapéutica y la neuroestimulación eléctrica espinal (20,(27)(28)(29).…”
Section: Contraindicación Relativaunclassified